Answers are grounded in this paper and cite their sources.
The outbreak of the new coronavirus SARS-CoV-2 has resulted in a global pandemic. Due to the lack of a specific drug against this virus, the current clinical management of this disease mainly depends on supportive care to reduce inflammatory responses and to keep the lung functioning. 1 Understanding the underlying immunopathology of coronavirus disease 2019 (COVID-19) is therefore of paramount importance for improving the current treatment. In this study, we found a distinct feature of adaptive immunity in severely affected patients, the coincidence of impaired cellular and enhanced humoral immune responses, suggesting that dysregulated adaptive immune responses advanced severe COVID-19. Interestingly, expression of Prothymosin alpha (PTMA), the proprotein of Thymosin alpha-1 (Tα1), was increased in a group of CD8 T memory stem cells accumulated during severe disease. We further showed that Tα1 slightly reduced T cell activation in vitro and promoted proliferation of effector T cells. Moreover, Tα1 treatment relieved the lymphopenia in COVID-19 patients. Our data suggest that early intervention of adaptive immune response might be critical for the prevention of severe COVID-19.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: